194 articles – 65 references  [version française]
Short view
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
Oger E., Alhenc-Gelas M., Lacut K., Blouch M.-T., Roudaut N., Kerlan V., Collet M., Abgrall J.-F., Aiach M., Scarabin P.-Y. et al
Arteriosclerosis, Thrombosis, and Vascular Biology 23, 9 (2003) 1671-6 - http://hal.univ-brest.fr/hal-00722263
Life Sciences/Human health and pathology
(12869355)
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
Emmanuel Oger1, Martine Alhenc-Gelas2, Karine Lacut1, Marie-Thérèse Blouch1, 3, Nathalie Roudaut4, Véronique Kerlan1, 4, Michel Collet1, 5, Jean-François Abgrall3, Martine Aiach2, Pierre-Yves Scarabin6, Dominique Mottier1,
1:  GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
Université de Bretagne Occidentale [UBO]
CHU de la Cavale Blanche Département de médecine interne et pneumologie 29609 BREST
France
2:  Risque thrombotique et mécanismes de l'hémostase
INSERM : U428 – IFR71 – Université Paris V - Paris Descartes
4, avenue de l'observatoire 75270 Paris Cedex 06
France
3:  Service d'hématologie biologique
CHU Brest
29200 Brest
France
4:  CHRU - Endocrino - Service d'Endocrinologie
CHRU Brest
Hôpital de la Cavale Blanche boulevard Tanguy Prigent 29609 BREST Cédex
France
5:  BREST - Gynéco-Obs - Service de Gynécologie-Obstétrique
CHRU Brest
Hôpital Morvan avenue Foch BREST
France
6:  CESP - Centre de recherche en épidémiologie et santé des populations
INSERM : U1018 – Université Paris XI - Paris Sud – Hôpital Paul Brousse – Assistance publique - Hôpitaux de Paris (AP-HP)
16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France
France
OBJECTIVE: Activated protein C (APC) resistance not related to the factor V Leiden mutation is a risk factor for venous thrombosis. Oral estrogen replacement therapy (ERT) has been reported to induce APC resistance. Little is known about the effect of transdermal estrogen. METHODS AND RESULTS: We enrolled 196 postmenopausal women who were randomly allocated to receive either 1 mg 17beta-estradiol orally (n=63) or 50 microg 17beta-estradiol transdermally per day (n=68), both associated with 100 mg progesterone daily or placebo (n=65) for 6 months. An activated partial thromboplastin time (APTT)-based test and the effect of APC on thrombin potential (ETP) were used. Oral ERT induced an ETP-based APC resistance compared with both placebo (P=0.006) and transdermal ERT (P<0.001), but there was no significant effect of transdermal ERT compared with placebo (P=0.191). There was no significant effect of ERT on the APTT-based APC sensitivity ratio. Prothrombin fragment 1+2 plasma levels were significantly higher after 6 months of treatment in women allocated to oral ERT compared with those on placebo and transdermal ERT and were positively and significantly correlated with changes in ETP-based APC sensitivity ratio. CONCLUSIONS: Our data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation. These results emphasize the importance of the route of estrogen administration.
English

Article in peer-reviewed journal
10.1161/01.ATV.0000087141.05044.1F
Arteriosclerosis, Thrombosis, and Vascular Biology (Arterioscler Thromb Vasc Biol)
Publisher American Heart Association
ISSN 1079-5642 (eISSN : 1524-4636)
international
2003-09-01
2003-07-17
23
9
1671-6

Administration – Cutaneous – Administration – Oral – Estrogens – Female – Humans – Postmenopause – Progesterone – Protein C